Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines

South African Medical Journal

Volumn 94, Issue 1, 2004, Pages 43-46

  Matjila, Maila J ^a   Phohu, Thabo C ^a   Banzhoff, Angelika ^b   Viviani, Simonetta ^c   Hoosen, Anwar A ^a   Bianchini, Massimo ^c   Nacci, Pantaleo ^c   Palweni, Chapman W ^a   Podda, Audino ^c   Whitfield, Michael ^a   Aspinall, Sanet ^d  

^a SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^b Chiron Behring GmbH & Co   (Germany)

^c CHIRON VACCINES   (Italy)

^d Clin Research Centres SA Pty Ltd   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; ORAL POLIOMYELITIS VACCINE;

ANTIBODY TITER; ARTICLE; BABY; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SKIN EDEMA; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; POLYSACCHARIDES, BACTERIAL; SAFETY; SOUTH AFRICA; VACCINATION; VACCINES, CONJUGATE;

EID: 10744233605     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13: 302-317.
2. Centers for Disease Control and Prevention. Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease: recommendations of the Immunisation Practices Advisory Committee (ACIP). Morb Mortal Wkly Rep 1985; 34: 201-205.
3. Munson RSJ, Kabeer MH, Lenoir AA, Granoff DM. Epidemiology and prospects for prevention of disease due to Haemophilus influenzae in developing countries. Rev Infect Dis 1989;11:S588-S597.
4. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349: 1191-1197.
5. Madhi Sa, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21: 315-321.
6. Department of Health, Republic of South Africa. Hib immunisation in South Africa. Epidemiological Comments 1999;1 (3): 4.
7. Hussey G, Hitchcock J, Schaaf H, et al. Epidemiology of invasive Haemophilus influenzae infections in Cape Town, South Africa. Ann Trop Paediatr 1994; 14: 97-103.
8. Moxon ER, Kroll IS. The role of bacterial polysaccharide capsules as virulence factors. In: Jann K, Jann B, eds. Current Topics in Microbiology and Immunology: Bacterial Capsules. Berlin: Springer-Verlag, 1990: 65-85.
9. Anderson P, Johnston R, Smith DH. Human serum activities against Haemophilus influenzae type b. J Clin Invest 1972; 51: 31-38.
10. Schneerson R, Rodrigues LP, Parke JC, et al. Immunity to disease caused by Haemophilus influenze type b. J Immunol 1971; 107: 1081-1089.
11. Weinberg G, Granoff D. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. J Pediatr 1988; 113: 621-631.
12. Shapiro ED. New vaccines against Haemophilus influenzae type b. Pediatr Clin North Am 1990; 37: 567-583.
13. Dintzis R. Rational design of conjugate vaccines. Pediatr Res 1992; 33: 376-385.
14. Constantino P, Viti S, Rappuoli R, Podda A. Semisynthetic vaccines against bacterial meningitis. Chemica Oggi 1991; March 13-15.
15. Kanra G, Viviani S, Yurdakok K, et al. Safety and immunogenicity of three Haemophilus influenzae type B vaccines. Proceedings of the 10th European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden, 28 -31 May 2000-06-15. Poster.
16. Mariani M, Luzzi E, Proietti D, et al. A competitive enzyme-linked immunosorbent assay for measuring the levels of serum antibody to Haemophilus influenzae type b. Clin Diagn Lab Immunol 1998; 5: 667-674.
17. Clopper CJ, Pearson ES. The use of confidential or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
18. Centers for Disease Control and Prevention. Progress toward eliminating Haemophilus influenzae type b disease among infants and children - United States, 1987 -97. Morb Mortal Wkly Rep 1998; 47: 993-998.
19. Nicol M, Huebner R, Mothupi R, et al. Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell petussis vaccine: a randomized trial. Pediatr Infect Dis J 2002; 21: 138-141.